Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Boilerplate Item 2.02 disclosure disclaimer regarding Section 18 liability and incorporation by reference.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Boilerplate Item 2.02 disclosure disclaimer regarding Section 18 liability and incorporation by reference
- No operating results or financial figures included in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted RP1 BLA resubmission; Class 1 review targets August 2, 2026, with advisory committee expected in late July
- RP1 showed 47.8% three-year survival and 32.9-month median overall survival in anti-PD-1-failed melanoma
- Cash, equivalents and short-term investments fell to $268.9M from $483.8M, funding operations into Q1 2027 under current plans
- Fiscal 2026 net loss widened to $313.9M from $247.3M as R&D rose to $221.2M and SG&A to $98.7M
- REVEAL Phase 2/3 trial evaluating RP2 in approximately 280 metastatic uveal melanoma patients, with transition expected Q1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.